Quoin Pharmaceuticals Ltd. — SEC Form D Filing

Quoin Pharmaceuticals Ltd. filed an SEC Form D on September 10, 2026, reporting $50.00M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
September 10, 2026
Amount reported
$50.00M
Industry
Pharmaceuticals
Website
https://quoinpharma.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: ISRAEL

Problem

Approximately 300 million people worldwide are affected by rare diseases, presenting significant challenges for those living with them. Specifically, Netherton Syndrome devastates the lives of patients and their families.

Solution

Quoin Pharmaceuticals develops therapeutic products to address rare diseases. They are currently conducting clinical studies to evaluate QRX003 for the treatment of Netherton Syndrome.

Why now

Increased scientific understanding and technological advancements are enabling the development of treatments for previously untreatable rare diseases. Growing awareness and advocacy for rare disease patients also create a more supportive market for specialized therapeutics.

Verdict

Investors said yes based on the potential for an orphan drug in an underserved market with a clear unmet medical need. This cleared because the narrative promised significant returns from a limited patient population with high willingness to pay once regulatory approval was achieved, not because it demonstrated broad market adoption or scalable commercialization. They were implicitly betting on successful clinical trials and regulatory approval, understanding that the small patient pool inherently capped the total addressable market.

Source: SEC EDGAR Form D filing